Biocon Balance Sheet Health
Financial Health criteria checks 2/6
Biocon has a total shareholder equity of ₹267.2B and total debt of ₹161.5B, which brings its debt-to-equity ratio to 60.4%. Its total assets and total liabilities are ₹571.3B and ₹304.1B respectively. Biocon's EBIT is ₹15.9B making its interest coverage ratio 2. It has cash and short-term investments of ₹26.5B.
Key information
60.4%
Debt to equity ratio
₹161.50b
Debt
| Interest coverage ratio | 2x |
| Cash | ₹26.50b |
| Equity | ₹267.20b |
| Total liabilities | ₹304.08b |
| Total assets | ₹571.28b |
Recent financial health updates
These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively
Sep 20
Is Biocon (NSE:BIOCON) A Risky Investment?
Jun 11These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively
Nov 13Is Biocon (NSE:BIOCON) Using Too Much Debt?
Jul 02Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly
Feb 26Is Biocon (NSE:BIOCON) Using Too Much Debt?
Jul 13Recent updates
Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results
Nov 02Why Investors Shouldn't Be Surprised By Biocon Limited's (NSE:BIOCON) Low P/E
Nov 01Do Biocon's (NSE:BIOCON) Earnings Warrant Your Attention?
Oct 14These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively
Sep 20Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors
Jun 29Is Biocon (NSE:BIOCON) A Risky Investment?
Jun 11Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50
Jun 11Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations
May 24Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50
May 23Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?
Mar 20Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next
Feb 12Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price
Jan 23Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price
Jan 03These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively
Nov 13Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)
Aug 03Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50
Jul 03Is Biocon (NSE:BIOCON) Using Too Much Debt?
Jul 02Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50
May 26Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)
Mar 28Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly
Feb 26Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate
Dec 17Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?
Sep 05Is Biocon (NSE:BIOCON) Using Too Much Debt?
Jul 13Financial Position Analysis
Short Term Liabilities: BIOCON's short term assets (₹151.5B) do not cover its short term liabilities (₹158.1B).
Long Term Liabilities: BIOCON's short term assets (₹151.5B) exceed its long term liabilities (₹146.0B).
Debt to Equity History and Analysis
Debt Level: BIOCON's net debt to equity ratio (50.5%) is considered high.
Reducing Debt: BIOCON's debt to equity ratio has increased from 30.5% to 60.4% over the past 5 years.
Debt Coverage: BIOCON's debt is well covered by operating cash flow (25%).
Interest Coverage: BIOCON's interest payments on its debt are not well covered by EBIT (2x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 14:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biocon Limited is covered by 42 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Meeta Shetty | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |
| Kunal Randeria | Axis Capital Limited |